Administration of rapamycin, an mTORc1-blocking drug inhibiting effector T cells but not Foxp3+ Tregs, with CD28 costimulatory molecule blockade [104] or with IL-2/anti-IL-2 immune complexes [105] demonstrated convincing capacities to delay diabetes in NOD mice. Here, IL2 is linked to diabetes mellitus.